Ignite Creation Date:
2025-12-24 @ 5:30 PM
Ignite Modification Date:
2026-01-04 @ 8:38 AM
Study NCT ID:
NCT03093168
Status:
UNKNOWN
Last Update Posted:
2019-02-27
First Post:
2017-03-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009101', 'term': 'Multiple Myeloma'}], 'ancestors': [{'id': 'D054219', 'term': 'Neoplasms, Plasma Cell'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D020141', 'term': 'Hemostatic Disorders'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D010265', 'term': 'Paraproteinemias'}, {'id': 'D001796', 'term': 'Blood Protein Disorders'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D006474', 'term': 'Hemorrhagic Disorders'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C024352', 'term': 'fludarabine'}, {'id': 'D003520', 'term': 'Cyclophosphamide'}], 'ancestors': [{'id': 'D010752', 'term': 'Phosphoramide Mustards'}, {'id': 'D009588', 'term': 'Nitrogen Mustard Compounds'}, {'id': 'D009150', 'term': 'Mustard Compounds'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D063088', 'term': 'Phosphoramides'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 10}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2017-02-15', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-03', 'completionDateStruct': {'date': '2020-02', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-02-25', 'studyFirstSubmitDate': '2017-03-15', 'studyFirstSubmitQcDate': '2017-03-27', 'lastUpdatePostDateStruct': {'date': '2019-02-27', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-03-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-09', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0', 'timeFrame': '6 months', 'description': 'Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0'}], 'secondaryOutcomes': [{'measure': 'Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm', 'timeFrame': '8 weeks', 'description': 'Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm'}, {'measure': 'Duration of CAR-positive T cells in circulation', 'timeFrame': '6 months', 'description': 'Duration of CAR-positive T cells in circulation'}, {'measure': 'Total number of CAR-positive T cells infiltrated into lymphoma tissue', 'timeFrame': '6 months', 'description': 'Total number of CAR-positive T cells infiltrated into lymphoma tissue'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Multiple Myeloma']}, 'referencesModule': {'references': [{'pmid': '37192741', 'type': 'DERIVED', 'citation': 'Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, Yan X, Zhang Q, Zhang M, Wang L, Hong R, Chang AH, Yu J, Fu S, Kong D, Li L, Wang Y, Li Z, Jiang H, Huang J, Liu Z, Su N, Wei G, Hu Y, Huang H. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol. 2023 Aug;202(3):517-524. doi: 10.1111/bjh.18873. Epub 2023 May 16.'}]}, 'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.', 'detailedDescription': 'Primary Objectives\n\n1. To determine the feasibility ad safety of BCMA CAR-T cells in treating patients with multiple myeloma.\n2. To determine in vivo dynamics and persistency of BCMA CAR-T cells.\n3. To access the efficacy of BCMA CAR-T cells in patients with multiple myeloma.\n\nSecondary Objectives\n\n1. To assess the bone marrow and tumor migration of BCMA CAR-T cells.\n2. To investigate the tumor killing capability of BCMA CAR-T cells in vitro\n3. To investigate the possibility of host immune response to the mouse derived BCMA scFv, and evaluate its correlation to CAR-T persistence.\n4. To correlate the subsets and differentiation of BCMA CAR-T cells to observed anti-tumor efficacy.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Expected survival \\> 12 weeks\n* Diagnosis of Multiple Myeloma by MWG criteria 20\n* Patients previously received at least 3 different prior treatment regimens for multiple myeloma, including alkylating agent, protein inhibitors, and immunomodulator, and have disease progression in the past 60 days\n* Important organs function enough to tolerate this therapy\n* At least 90 days after stem cell transplantation\n* Clinical performance status of ECOG score 0-4\n* Accessible to intravenous injection, and no white blood cell collection contraindications\n* Sexually active patients must be willing to utilize one of the more effective birth control methods for 30 days after the CTL infusion. Male partner should use a condom\n* Able to understand and sign the Informed Consent Document.\n\nExclusion Criteria:\n\n* Patients with symptoms of central nervous system\n* Patients with second malignancies in addition to multiple myeloma\n* Active hepatitis B or C, HIV infections\n* Any other active diseases could affect the enrollment of this trial\n* Suffering severe cardiovascular or respiratory disease\n* Poorly controlled hypertension\n* Long term use of immunosuppressive agents after organ transplantation, except currently receiving or recently received glucocorticoid treatment\n* A history of mental illness and poorly controlled\n* Screening showing target cell transduction efficacy is lower than 30%, or T cell proliferation is not enough for infusion (less than 5 fold)\n* Occurrence of unstable pulmonary embolism, deep vein thrombosis, or other major arterial/venous thromboembolic events 30 days prior to assignment\n* Women of child-bearing potential who are pregnant or breastfeeding during therapy, or have a planned pregnancy with 2 months after therapy\n* Women of child-bearing potential who are not willing to practice birth control from the time of enrollment on this study and for 2 months after receiving the preparative regimen. Women of child bearing potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion\n* Active systemic infections or uncontrolled infection within 14 days prior enrollment\n* Subjects suffering disease affects the understanding of informed consent or complying with study protocol'}, 'identificationModule': {'nctId': 'NCT03093168', 'briefTitle': 'BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma', 'organization': {'class': 'OTHER', 'fullName': 'The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine'}, 'officialTitle': 'A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Subjects With BCMA-positive Multiple Myeloma', 'orgStudyIdInfo': {'id': 'anti-BCMA CART'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'anti-BCMA CAR-T', 'description': 'Administration of anti-BCMA:TCRζ-4-1-BB CAR-T cells to patients with multiple myeloma', 'interventionNames': ['Biological: Anti-BCMA CAR-T cells', 'Drug: Fludarabine', 'Drug: Cyclophosphamide']}], 'interventions': [{'name': 'Anti-BCMA CAR-T cells', 'type': 'BIOLOGICAL', 'description': 'Retroviral vector-transduced autologous T cells to express anti-BCMA CAR', 'armGroupLabels': ['anti-BCMA CAR-T']}, {'name': 'Fludarabine', 'type': 'DRUG', 'description': 'dose: 25mg/m2/d', 'armGroupLabels': ['anti-BCMA CAR-T']}, {'name': 'Cyclophosphamide', 'type': 'DRUG', 'description': 'Dose: 40mg/kg', 'armGroupLabels': ['anti-BCMA CAR-T']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Zhengzhou', 'state': 'Henan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Zhi Cheng, M.D.', 'role': 'CONTACT', 'email': 'clinicaltrials.chengzhi@outlook.com', 'phone': '+(86)-139-3852-6995'}], 'facility': 'Henan Province of TCM', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine', 'class': 'OTHER'}, 'collaborators': [{'name': 'Hrain Biotechnology Co., Ltd.', 'class': 'INDUSTRY'}, {'name': 'First Affiliated Hospital of Wenzhou Medical University', 'class': 'OTHER'}, {'name': 'Shanghai Changzheng Hospital', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}